The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Open accessAbstract
IMPORTANCE: The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics. OBJECTIVE: To reveal genomic characteristics from cfDNA associated with clinical outcomes during enzalutamide treatment. DESIGN, SETTING, AND PARTICIPANTS: Plasma samples were obtained from August 4, 2013, to July 31, 2015, at a single academic institution (British Columbia Cancer Agency) from 65 patients with mCRPC. We collected temporal plasma samples (at baseline, 12 weeks, end of treatment) for circulating cfDNA and performed array comparative genomic hybridization copy number profiling and deep AR gene sequencing. Samples collected at end of treatment were also subjected to targeted sequencing of 19 prostate cancer-associated genes. EXPOSURE: Enzalutamide, 160 mg, daily orally. MAIN OUTCOMES AND MEASURES: Prostate-specific antigen response rate (decline ≥50% from baseline confirmed ≥3 weeks later). Radiographic (as per Prostate Cancer Working Group 2 Criteria) and/or clinical progression (defined as worsening disease-related symptoms necessitating a change in anticancer therapy and/or deterioration in Eastern Cooperative Group performance status ≥2 levels). RESULTS: The 65 patients had a median (interquartile range) age of 74 (68-79) years. Prostate-specific antigen response rate to enzalutamide treatment was 38% (25 of 65), while median clinical/radiographic progression-free survival was 3.5 (95% CI, 2.1-5.0) months. Cell-free DNA was isolated from 122 of 125 plasma samples, and targeted sequencing was successful in 119 of 122. AR mutations and/or copy number alterations were robustly detected in 48% (31 of 65) and 60% (18 of 30) of baseline and progression samples, respectively. Detection of AR amplification, heavily mutated AR (≥2 mutations), and RB1 loss were associated with worse progression-free survival, with hazard ratios of 2.92 (95% CI, 1.59-5.37), 3.94 (95% CI, 1.46-10.64), and 4.46 (95% CI, 2.28-8.74), respectively. AR mutations exhibited clonal selection during treatment, including an increase in glucocorticoid-sensitive AR L702H and promiscuous AR T878A in patients with prior abiraterone treatment. At the time of progression, cfDNA sequencing revealed mutations or copy number changes in all patients tested, including clinically actionable alterations in DNA damage repair genes and PI3K pathway genes, and a high frequency (4 of 14) of activating CTNNB1 mutations. CONCLUSIONS AND RELEVANCE: Clinically informative genomic profiling of cfDNA was feasible in nearly all patients with mCRPC and can provide important insights into enzalutamide response and resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
Self-citationTargeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., Kasibhatla, S., Schuller, A. G., Li, A. G., Cheng, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314239110 · Cited by 831
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
Miyamoto, D. T., Zheng, Y., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., Desai, R., Fox, D. B., Brannigan, B. W., Trautwein, J., et al. (2015) · Science · doi:10.1126/science.aab0917 · Cited by 705
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Korpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 561
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Self-citationBeltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Plasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 441
the ICGC Prostate Group, Cooper, C. S., Eeles, R., Wedge, D. C., Van Loo, P., Gundem, G., Alexandrov, L. B., Kremeyer, B., Butler, A., Lynch, A. G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3221 · Cited by 434
Alternatively spliced androgen receptor variants
Dehm, S. M., & Tindall, D. J. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0141 · Cited by 380
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Hong, M. K. H., Macintyre, G., Wedge, D. C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L. B., Sloggett, C., Cmero, M., Marass, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7605 · Cited by 372
Beta-catenin mutations in human prostate cancer.
Voeller, H. J., Truica, C., & Gelmann, E. P. (1998) · PubMed · Cited by 371
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343
Self-citationLalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Self-citationTumor clone dynamics in lethal prostate cancer
Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.-S., Pezaro, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009448 · Cited by 340
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Self-citationSchwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Chen, E. J., Sowalsky, A. G., Gao, S., Cai, C., Voznesensky, O., Schaefer, R., Loda, M., True, L. D., Ye, H., Troncoso, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1220 · Cited by 182
Azad, A. A., Eigl, B. J., Murray, R. N., Kollmannsberger, C., & Chi, K. N. (2015) · European Urology · doi:10.1016/j.eururo.2014.06.045 · Cited by 164
Self-citationCastration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
Sridhar, S. S., Freedland, S. J., Gleave, M. E., Higano, C. S., Mulders, P., Parker, C. C., Sartor, O. A., & Fred Saad, C. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.008 · Cited by 152
Self-citationTargeting the adaptive molecular landscape of castration‐resistant prostate cancer
Wyatt, A. W., & Gleave, M. E. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303701 · Cited by 138
Self-citationDalal, K., Roshan‐Moniri, M., Sharma, A., Li, H., Ban, F., Hessein, M., Hsing, M., Singh, K., Leblanc, E., Dehm, S. M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553818 · Cited by 135
Binding kinetics of fluticasone propionate to the human glucocorticoid receptor
Högger, P., & Rohdewald, P. J. (1994) · Steroids · doi:10.1016/0039-128x(94)90054-x · Cited by 132
Clinical use of novel urine and blood based prostate cancer biomarkers: A review
Dijkstra, S., Mulders, P., & Schalken, J. A. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.10.023 · Cited by 131
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
Chi, K. N., Hotte, S. J., Joshua, A. M., North, S. A., Wyatt, A. W., Collins, L. L., & Fred Saad, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv267 · Cited by 123
Self-citationNovel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
de Leeuw, R., Berman-Booty, L. D., Schiewer, M. J., Ciment, S. J., Den, R. B., Dicker, A. P., Kelly, W. K., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1358 · Cited by 101
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
Lorente, D., Mateo, J., Zafeiriou, Z., Smith, A. D., Sandhu, S. K., Ferraldeschi, R., & Bono, J. S. D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.345 · Cited by 98
Krishnan, A. V., Zhao, X.-Y., Swami, S., Brive, L., Peehl, D. M., Ely, K. R., & Feldman, D. (2002) · Endocrinology · doi:10.1210/en.143.5.1889 · Cited by 78
Munuganti, R. S. N., Hassona, M. D. H., Leblanc, E., Frewin, K., Singh, K., Ma, D., Ban, F., Hsing, M., Adomat, H. H., Lallous, N., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.012 · Cited by 76
van de Wijngaart, D. J., Molier, M., Lusher, S. J., Hersmus, R., Jenster, G. W., Trapman, J., & Dubbink, H. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039958 · Cited by 66
Lorente, D., Omlin, A. G., Ferraldeschi, R., Pezaro, C. J., Pérez-López, R., Mateo, J., Altavilla, A., Zafeirou, Z., Tunariu, N., Parker, C. C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.531 · Cited by 62
Azad, A., Leibowitz‐Amit, R., Eigl, B. J., Lester, R. E., Wells, J. C., Murray, R. N., Kollmannsberger, C., Heng, D. Y. C., Joshua, A. M., & Chi, K. N. (2014) · The Prostate · doi:10.1002/pros.22872 · Cited by 49
Self-citation
Cited by
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citation
Metadata
- Authors
- Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., Haegert, A., Warner, E. W., Mo, F., Brahmbhatt, S., Shukin, R., Le Bihan, S., Gleave, M. E., Nykter, M., Collins, C. C., & Chi, K. N.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-12-01
- Volume
- 2
- Issue
- 12
- Pages
- 1598
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2403998898
- Cited by
- 373
- References
- 45
- FWCI
- 42.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.